These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 32480098)

  • 1. Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis.
    Xie W; Yang X; Ji L; Zhang Z
    Semin Arthritis Rheum; 2020 Aug; 50(4):598-607. PubMed ID: 32480098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
    Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
    JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
    Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
    Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis.
    Xie W; Hou Y; Xiao S; Zhang X; Zhang Z
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38413170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study.
    Tam HW; Chen CM; Leong PY; Chen CH; Li YC; Wang YH; Lin LC; Chiou JY; Wei JC
    Int J Rheum Dis; 2018 Aug; 21(8):1591-1599. PubMed ID: 29372595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis.
    Lillegraven S; Greenberg JD; Reed GW; Saunders K; Curtis JR; Harrold L; Hochberg MC; Pappas DA; Kremer JM; Solomon DH
    PLoS One; 2019; 14(1):e0210459. PubMed ID: 30673733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoid use in rheumatoid arthritis patients and the onset of pneumonia: a systematic review and meta-analysis.
    Elsouri KN; Arboleda V; Basbous L; Heiser S; Collins DP; Ragusa P; Baxter C; Cabrera D; Akhand T; Stermer E; Sharma K; Seguro C; Hardigan P; Kesselman M; Beckler MD
    J Osteopath Med; 2023 Apr; 123(4):179-186. PubMed ID: 36691851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials.
    Mazouyès A; Clay M; Bernard AC; Gaudin P; Baillet A
    Joint Bone Spine; 2017 Oct; 84(5):563-570. PubMed ID: 27989589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
    Mary J; De Bandt M; Lukas C; Morel J; Combe B
    J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
    Jones G; Hall S; Bird P; Littlejohn G; Tymms K; Youssef P; Chung E; Barrett R; Button P
    Int J Rheum Dis; 2018 Aug; 21(8):1581-1590. PubMed ID: 29205926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy.
    Antohe JL; Bili A; Sartorius JA; Kirchner HL; Morris SJ; Dancea S; Wasko MC
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):215-21. PubMed ID: 21972198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
    Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
    Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials.
    Siu S; Haraoui B; Bissonnette R; Bessette L; Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Kraft J; Lynde C; Gulliver W; Keeling S; Dutz J; Pope JE
    Arthritis Care Res (Hoboken); 2015 May; 67(6):754-64. PubMed ID: 25418272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Singh S; Fumery M; Singh AG; Singh N; Prokop LJ; Dulai PS; Sandborn WJ; Curtis JR
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):561-576. PubMed ID: 30875456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.
    Ozen G; Pedro S; Michaud K
    J Rheumatol; 2021 May; 48(5):648-655. PubMed ID: 32801134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study.
    Desai RJ; Eddings W; Liao KP; Solomon DH; Kim SC
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):457-66. PubMed ID: 25302481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
    Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies.
    Xie W; Yang X; Huang H; Gao D; Ji L; Zhang Z
    Semin Arthritis Rheum; 2020 Oct; 50(5):930-937. PubMed ID: 32906027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.